The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

Pfizer120 enrolled

Overview

Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Candidiasis

Interventions

Anidulafungin, VER002DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Positive culture plus at least one clinical sign and symptom consistent with invasive candidiasis preferably within 96 hours of the proposed first dose of study drug * Life expectancy: greater than 72 hours Exclusion Criteria: * Pregnant Females * Treatment with other investigational drug(s) within 4 weeks * Hypersensitivity to anidulafungin or echinocandin therapy * Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid

Locations (1)

Versicor, Inc.

King of Prussia, Pennsylvania, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.